SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

18 May 2022 Evaluate
A fair growth of 13.49% in the revenue at Rs. 28553.90 millions was reported in the March 2022 quarter as compared to Rs. 25159.60 millions during year-ago period.The Net Loss for the quarter ended March 2022 is Rs. -358.90 millions as compared to Net Profit of Rs. 3163.60 millions of corresponding quarter ended March 2021The company reported a good operating profit of 5171.50 millions compared to 4911.20 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 28553.90 25159.60 13.49 117716.70 110559.30 6.47 117716.70 110559.30 6.47
Other Income 570.30 660.70 -13.68 2169.90 1290.90 68.09 2169.90 1290.90 68.09
PBIDT 5171.50 4911.20 5.30 4261.30 21731.50 -80.39 4261.30 21731.50 -80.39
Interest 245.80 123.10 99.68 734.70 406.20 80.87 734.70 406.20 80.87
PBDT 4925.70 4788.10 2.87 3526.60 21325.30 -83.46 3526.60 21325.30 -83.46
Depreciation 1310.20 1250.10 4.81 5141.90 5028.30 2.26 5141.90 5028.30 2.26
PBT 3615.50 3538.00 2.19 -1615.30 16297.00 -109.91 -1615.30 16297.00 -109.91
TAX 3974.40 374.40 961.54 271.70 3710.80 -92.68 271.70 3710.80 -92.68
Deferred Tax 3419.40 236.70 1344.61 -306.30 82.30 -472.17 -306.30 82.30 -472.17
PAT -358.90 3163.60 -111.34 -1887.00 12586.20 -114.99 -1887.00 12586.20 -114.99
Equity 909.00 907.40 0.18 909.00 907.40 0.18 909.00 907.40 0.18
PBIDTM(%) 18.11 19.52 -7.22 3.62 19.66 -81.58 3.62 19.66 -81.58

Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: